drugset / Trial / NCT00397488
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Phase 2
Completed
78 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with progressive metastatic transitional cell cancer of the urothelium.
Timeline
- Start
- 2006-09
- Primary completion
- 2012-02
- Completion
- 2012-02